Genetic Signatures (GSS) H2 2024 earnings summary

Executive summary

• Revenue declined 42% year-over-year to $9.8 million, mainly due to a temporary product withdrawal in Australia and reduced respiratory testing demand.

• Net loss increased 27% to $17.9 million, reflecting lower sales and gross margin compression.

• Achieved FDA 510(k) clearance for the EasyScreen Gastrointestinal Parasite Detection Kit, enabling US market entry.

• Completed two capital raises totaling $34.9 million, strengthening the balance sheet.

• Leadership transition: Dr. John Melki stepped down as CEO, with Allison Rossiter to commence as CEO in September 2024.

Financial highlights

• Revenue: $9.8 million, down from $16.9 million year-over-year.

• Net loss: $17.9 million, compared to $14.1 million prior year.

• Gross margin: 53%, down from 60% due to lower production volumes and inventory obsolescence.

• Cash on hand: $36.3 million as of June 30, 2024; company remains debt free.

• Net operating cash outflow: $10.1 million.

Outlook and guidance

• Focus on US commercial launch of the EasyScreen Gastrointestinal Parasite Detection Kit.

• Expectation of solid revenue growth in FY2025 and beyond, driven by US market entry.

• Plans to resume paused R&D and instrument development as cash flows improve.